检索结果-南通市图书馆

声学技术 1975年第1期6卷 124-138页

作者： r.seynaeve E.Hug G.Vettori 宗杰琍 SAC LANT 反潜研究中心

一、Saclant 研究中心的人—机互作用式时间系列分析系统(ITSA)1.引言本文第一部分旨在叙进 Saclant 研究中心研制的会话式信号处理系统。这个系统在很多科研项目中被广泛采用,并正在提供多样的成果。它和同样领域中我们以前的系统大为... 详细信息

一、Saclant 研究中心的人—机互作用式时间系列分析系统(ITSA)1.引言本文第一部分旨在叙进 Saclant 研究中心研制的会话式信号处理系统。这个系统在很多科研项目中被广泛采用,并正在提供多样的成果。它和同样领域中我们以前的系统大为不同,它面向科学工作者和计算机两者间的相互作用,更适合在实际实验中应用。

关键词：互作用声纳声学仪器优先度计算机系统电脑系统变化率信号处理系统时间序列分析成批处理批处理数据处理时间间隔磁盘容量信道信息通路脉冲响应时间特性实验工具多道程序设计序列微型计算机个人电脑电子数字计算机

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

宫颈原发性神经外胚层肿瘤1例报道

引用

世界核心医学期刊文摘（妇产科学分册） 2006年第1期2卷 49-50页

作者： Snijders-Keilholz A. Ewing P. seynaeve C. Burger C. W. 杨晓梅(译) 马超(校) A. Snijders-Keilholz Erasmus University Medical Center Daniel Den Hoed Cancer Center PO-Box 5201 3008 AE Rotterdam Netherlands 不详

Background. Peripheral primitive neuroectodermal tumor (PNET) of the cervix uteri is extremely rare. Between 1987 and 2002, there have been eight cases described in the English literature. The treatment policies in these eight cases differed considerably, partly due to the rarity of the disease and to differing time periods of diagnosis and treatment. Case. At the end of 2002, a 21- year- old woman presented with a PNET of the cervix uteri at our institute, the Erasmus Medical Center. For the appropriate treatment in this case, we reviewed the literature and decided that the treatment should be different from the local surgical treatment followed by additional treatments as most of the earlier reports describe. Conclusion. In view of the current knowledge of PNET belonging to the family of Ewing’ s sarcoma, and the improvement of treatment outcome in these tumors due to dose-intensive neo-adjuvant chemotherapy, patients with PNET of the cervix should be treated in accordance to the protocol for bony Ewing’ s sarcoma with multimodality therapy by means of induction chemotherapy, surgery, and consolidation chemotherapy.

关键词：神经外胚层肿瘤原发性宫颈 Ewing肉瘤 Erasmus 治疗方法 PNET 文献记载治疗方案医疗中心

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors?

引用

Advances in Breast Cancer research 2015年第4期4卷 87-99页

作者： Ellen G. Engelhardt Mieke Kriege Maartje J. Hooning Caroline seynaeve rob A. E. M. Tollenaar Christina J. van Asperen Margreet G. E. M. Ausems Lonneke V. van de Poll-Franse Stella Mook Senno Verhoef Matti A. rookus HEBON Collaborators Marjanka K. Schmidt Division of Psychosocial research and Epidemiology Netherlands Cancer Institute Amsterdam The Netherlands Family Cancer Clinic Department of Medical Oncology Erasmus MC-Daniel den Hoed Cancer Centre Rotterdam The Netherlands Department of Surgery Leiden University Medical Centre Leiden The Netherlands Department of Clinical Genetics Leiden University Medical Centre Leiden The Netherlands Department of Medical Genetics University Medical Centre Utrecht Utrecht The Netherlands Eindhoven Cancer registry Comprehensive Cancer Centre South Eindhoven The Netherlands Department of radiation Oncology Netherlands Cancer Institute Amsterdam The Netherlands Family Cancer Clinic Netherlands Cancer Institute Amsterdam The Netherlands Hereditary Breast and Ovarian Cancer Netherlands (HEBON) Collaborators (see end of article for full list of HEBON collaborators and affiliations) Division of Molecular Pathology Netherlands Cancer Institute Amsterdam The Netherlands

Objective: It is unclear if and to what extent family history of breast/ovarian cancer or BrCA1/2-mutation carriership influences breast cancer treatment strategy. We investigated whether treatment differed between patients from BrCA1/2 families and those unselected for family history. Methods: We included 478 BrCA1/2-related patients referred for genetic testing before or after diagnosis. Two references were used: 13,498 population-based and 6896 hospital-based patients. Surgical treatment and adjuvant chemotherapy use was analyzed using logistic regression models, stratified by tumor size, nodal status, age at and period of diagnosis, and estrogen receptor status (Er). results: BrCA1/2 cases aged 35 - 52 years at diagnosis and/or with tumors re more likely to have undergone a modified radical mastectomy (Odd ratios (Or) ranging from 2.8 to 5.1) compared to the references. This effect was most pronounced in patients treated after 1995 (Or 5.7 to 10.3). Compared to the reference groups, chemotherapy was more often administered to BrCA1 and Er-negative BrCA1/2-cases irrespective of age and nodal status (Or 1.9 to 24.3). Conclusion: After 1995 treatment of BrCA1/2-associated patients consisted notably of more mastectomies and adjuvant chemotherapy than their population-based counterparts with the same tumor characteristics. There is a need to be aware of such differences in daily practice and interpretation of survival studies on BrCA1/2 mutation carriers.

关键词： BrCA1/2 Familial Breast Cancer Treatment Adjuvant Chemotherapy Mastectomy Breast Conserving Therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：